🟢 Definium Therapeutics is trading 8% up today after positive Phase 3 Voyage anxiety results

Definium Therapeutics is trading at $44.22 (+8.09%) after positive Phase 3 Voyage results for DT120 ODT in generalized anxiety disorder.

• The study met its primary and all key secondary efficacy endpoints, with a placebo-adjusted HAM-A improvement of 5.4 points and p<0.0001.
• Independent coverage reported shares jumped 20% premarket before moderating during regular trading.
• Broader markets are also modestly higher, but the clinical readout is the clear primary catalyst.